HF biomarker


McDonald and Wilkinson (2017) and other researchers are advocating for the increased use of B-type natriuretic peptide (BNP) assay as part of the strategies for heart failure diagnosis and prevention. The use of the biomarkers has been shown to improve diagnostic accuracy for HF and provide prognostic information after more than a decade of use with recommendations by national and international cardiovascular organizations.
Fu, et al (2018) describe the actions of usefulness of natriuretic peptides as follows:

NPs represent body's own antihypertensive system, and provide compensatory protection to counterbalance vasoconstrictor-mitogenic-sodium retaining hormones, released by renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). NPs play central roles in regulation of heart failure (HF), and are inactivated through not only NP receptor-C, but also neutral endopeptidase (NEP), dipeptidyl peptidase-4 and insulin degrading enzyme. Both BNP and N-terminal proBNP are useful biomarkers to not only make the diagnosis and assess the severity of HF, but also guide the therapy and predict the prognosis in patients with HF.

 


References

Fu, S., Ping, P., Wang, F. & Luo, L. (2018). Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 12, 12:2.

McDonald, K., Wilkinson, M. (2017). Evolving Use of Natriuretic Peptides as Part of Strategies for Heart Failure Prevention. Clin Chem. 63(1), 66-72.


 

© RnCeus.com